HIV-1 RT mutations in patients after 24 weeks of tenofovir disoproxil fumarate (formerly PMPA prodrug) therapy

被引：0
|
作者：
Miller, MD [1 ]
Margot, NA [1 ]
Mills, R [1 ]
McGowan, I [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
ANTIVIRAL RESEARCH | 2000年 / 46卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
8
引用
收藏
页码：A37 / A37
页数：1
相关论文
共 50 条
  • [21] HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    D'Antoni, Michelle L.
    Andreatta, Kristen
    Chang, Silvia
    Cox, Stephanie
    Hindman, Jason T.
    Avihingsanon, Anchalee
    Martin, Hal
    Vanderveen, Laurie A.
    Callebaut, Christian
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (04) : 380 - 384
  • [22] Evaluation of lipid levels and cardiovascular risk in HIV-infected patients 24 weeks after being switched from a tenofovir disoproxil fumarate to a tenofovir alafenamide containing regimen in a clinic in Puerto Rico
    Melendez-Rivera, I.
    Ayala, K.
    ANTIVIRAL THERAPY, 2018, 23 : A50 - A50
  • [23] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Greg L. Plosker
    Drugs, 2013, 73 : 279 - 291
  • [24] Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient
    Karris, Maile Young
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2017, 33 (07) : 718 - 722
  • [25] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Plosker, Greg L.
    DRUGS, 2013, 73 (03) : 279 - 291
  • [26] Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model
    Destache, Christopher J.
    Mandal, Subhra
    Yuan, Zhe
    Kang, Guobin
    Date, Abhijit A.
    Lu, Wuxun
    Shibata, Annemarie
    Pham, Rachel
    Bruck, Patrick
    Rezich, Michael
    Zhou, You
    Vivekanandan, Renuga
    Fletcher, Courtney V.
    Li, Qingsheng
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (06) : 3633 - 3639
  • [27] SAFETY AND EFFICACY OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT-NAIVE JAPANESE PATIENTS WITH HIV-1 INFECTION
    Yajima, K.
    Yagura, H.
    Yukawa, S.
    Hirota, K.
    Ikuma, M.
    Kasai, D.
    Watanabe, D.
    Nishida, Y.
    Uehira, T.
    Shirasaka, T.
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A237 - A237
  • [28] Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy
    Nishijima, Takeshi
    Kurosawa, Takuma
    Tanaka, Noriko
    Kawasaki, Yohei
    Kikuchi, Yoshimi
    Oka, Shinichi
    Gatanaga, Hiroyuki
    AIDS, 2016, 30 (10) : 1563 - 1571
  • [29] Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide
    Margot, Nicolas A.
    Wong, Pamela
    Kulkarni, Rima
    White, Kirsten
    Porter, Danielle
    Abram, Michael E.
    Callebaut, Christian
    Miller, Michael D.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (06): : 920 - 927
  • [30] Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV
    不详
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) : I21 - I21
12345